TENNANT CO
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Leases
- Leases
We lease facilities, vehicles and equipment under the operating lease agreements, which include both monthly and longer-term arrangements.
Certain operating leases for vehicles contain residual value guarantee provisions, which would generally become due at the expiration of the operating lease agreement if the fair value of the leased vehicles is less than the guaranteed residual value. As of December 31, 2025, the aggregate residual value guarantee related to these leases was approximately$25.5 million. We believe the likelihood of funding the guarantee obligation under any provision of the operating lease agreement is remote.
The lease assets and liabilities as of December 31 were as follows:
| Leases | Classification | 2025 | 2024 |
|---|---|---|---|
| Assets | |||
| Operating lease assets | Operating lease assets | $56.9 | $54.6 |
| Finance lease assets | Property, plant and equipment(a) | 1.1 | 1.1 |
| Total leased assets | $58.0 | $55.7 | |
| Liabilities | |||
| Current: | |||
| Operating | Other current liabilities | $21.7 | $18.5 |
| Finance | Current portion of long-term debt | 0.4 | 0.5 |
| Noncurrent: | |||
| Operating | Long-term operating lease liabilities | 35.5 | 36.3 |
| Finance | Long-term debt | 0.7 | 0.7 |
| Total lease liabilities | $58.3 | $56.0 | |
| (a) | Finance lease assets are recorded net of accumulated amortization of $0.8 million and $0.3 million, and as of December 31, 2025 and December 31, 2024, respectively. |
|---|
The lease cost for the three years ended December 31 was as follows:
| Lease Cost | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating lease cost(a) | $31.7 | $30.1 | $28.9 |
| Finance lease cost(b) | 0.5 | 0.2 | 0.1 |
| Total lease cost | $32.2 | $30.3 | $29.0 |
| (a) | Includes short-term lease costs of $4.3 million, $6.2 million, and $5.9 million and variable lease costs of $3.0 million, $2.4 million and $4.2 million for the years ended December 31, 2025 and December 31, 2024, respectively. |
|---|
| (b) | Includes amortization of leased assets and interest on lease liabilities. |
|---|
The maturity of lease liabilities as of December 31, 2025 was as follows:
| Maturity of Lease Liabilities | Operating Leases | Finance Leases | Total |
|---|---|---|---|
| 2026 | $24.3 | $0.4 | $24.7 |
| 2027 | 19.1 | 0.4 | 19.5 |
| 2028 | 11.2 | 0.3 | 11.5 |
| 2029 | 4.4 | 0.1 | 4.5 |
| 2030 | 1.6 | — | 1.6 |
| Thereafter | 2.1 | — | 2.1 |
| Total lease payments | $62.7 | $1.2 | $63.9 |
| Less: Interest | (5.5) | (0.1) | (5.6) |
| Present value of lease liabilities | $57.2 | $1.1 | $58.3 |
The lease term and discount rate as of December 31 were as follows:
| Lease Term and Discount Rate | 2025 | 2024 |
|---|---|---|
| Weighted-average remaining lease term (years): | ||
| Operating leases | 3.2 | 3.5 |
| Finance leases | 3.2 | 4.0 |
| Weighted-average discount rate: | ||
| Operating leases | 6.1% | 6.1% |
| Finance leases | 5.6% | 5.2% |
Other information related to cash paid related to lease liabilities and lease assets obtained for the years ended December 31 was as follows:
| Other Information | 2025 | 2024 |
|---|---|---|
| Cash paid for amounts included in the measurement of lease liabilities: | ||
| Operating cash flows from operating leases | $24.5 | $21.3 |
| Operating cash flows from finance leases | 0.1 | — |
| Financing cash flows from finance leases | 0.4 | 0.2 |
| Lease assets obtained in exchange for new finance lease liabilities | 0.8 | 1.0 |
| Lease assets obtained in exchange for new operating lease liabilities | 18.8 | 34.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.